Browse Title Index


 
Issue Title
 
Vol 13, No 1 (2012) A changing journal in a changing health care Details   HTML   PDF
Mario Eandi
 
Vol 14, No 4 (2013) A cost-minimization analysis of combination therapy in hypertension: fixed-dose vs extemporary combinations Abstract   HTML   PDF
Marco Bellone, Pierluigi Sbarra
 
Vol 18, No 1 (2017) A general model for the estimation of societal costs of lost production and informal care in Italy Abstract   HTML   PDF
Lorenzo Pradelli, Gianni Ghetti
 
Vol 15, No 3 (2014) A new decision model for economic evaluation of novel therapies for HCV Abstract   HTML   PDF
Matteo Ruggeri, Americo Cicchetti, Silvia Coretti, Carlo Cammà, Nicola Caporaso, Antonio Gasbarrini
 
Vol 14, No 1 (2013) A pharmacoeconomic analysis of the use of single MMC instillation in low risk NMIBC in Italy Abstract   HTML   PDF
Renzo Colombo, Federico Pellucchi, Lorenzo Rocchini, Carmen Maccagnano, Pablo Katz, Valeria Pegoraro
 
Vol 13, No 2S (2012) Abruzzo Abstract   HTML   PDF
Roberto Gasparini, Donatella Panatto, Bruna Dirodi, Rosa Prato, Gianni Amunni, Valter Turello, Luigi Sudano, Paolo Cristoforoni, Sara Boccalini, Paolo Bonanni
 
Vol 9, No 1S (2008) Abruzzo Abstract   PDF
Maria Caterina Cavallo, Filippo Cipriani, Simone Gerzeli, Nadia Demarteau, Alessia Marocco, Francesco Bamfi
 
Vol 13, No 1 (2012) Access to pharmaceutical products in six European countries – analysis of different pharmaceutical distribution systems Abstract   HTML   PDF
Evelyn Walter, Aline Dragosits, Monira Said
 
Vol 6, No 4 (2005) Adefovir dipivoxil nella terapia dell’epatite B cronica: profilo farmacologico clinico ed economico Abstract   PDF
Lorenzo Pradelli, Mario Eandi
 
Vol 12, No 2S (2011) Aderenza e persistenza: due elementi chiave per la determinazione dell’efficacia terapeutica in usual care Details   PDF
Giampiero Mazzaglia, Ovidio Brignoli, Achille P. Caputi, Claudio Cricelli
 
Vol 13, No 1 (2012) Adherence to therapeutic guidelines among patients treated with statins. Results from STAR study Abstract   HTML   PDF
Luca Degli Esposti, Diego Sangiorgi, Gabriele Lazzeri, Stefano Buda
 
Vol 12, No 2 (2011) Adherence to treatment and anticoagulation control in vitamin K antagonists-treated patients: an administrative databases analysis in a large Italian population Abstract   HTML   PDF
Luca Degli Esposti, Diego Sangiorgi, Giuseppe Di Pasquale, Gian Franco Gensini, Ido Iori, Stefano Buda, Ezio Degli Esposti
 
Vol 3, No 1 (2002) ALPRAZOLAM: profilo farmacoeconomico nei disturbi d’ansia e da attacchi di panico Abstract   PDF
Mario Eandi
 
Vol 1, No 2 (2000) Analisi comparativa del mercato dei dispositivi per incontinenza in cinque paesi europei Abstract   PDF
Dante Cornago, Livio Garattini
 
Vol 6, No 4 (2005) Analisi costi-efficacia di 90Y-ibritumomab tiuxetano (Zevalin®) vs. terapie attualmente disponibili nel trattamento dei pazienti affetti da Linfoma Non-Hodgkin (LNH) refrattario o recidivato Abstract   PDF
Carlo Lazzaro, Manolo Beelke
 
Vol 5, No 2 (2004) Analisi Costo Minimizzazione delle preparazioni di Interferon Beta per il trattamento della Sclerosi Multipla Abstract   PDF
Francesco Macchia, Pierluigi Russo, Luciano Caprino
 
Vol 3, No 2 (2002) Analisi costo/efficacia della doxofillina vs. teofillina nella terapia dell’asma cronica reversibile dell’adulto Abstract   PDF
Mario Eandi, Elisa Berno, Lorenzo Pradelli
 
Vol 5, No 4 (2004) Analisi costo/efficacia di sevelamer nel trattamento dell’iperfosforemia del paziente in dialisi Abstract   PDF
Mario Eandi, Nicola Giotta, Gaia Santagostino Barbone
 
Vol 6, No 4 (2005) Analisi Costo-Efficacia di Amfotericina B Liposomiale (L-AmB) versus Amfotericina B Complesso Lipidico (ABLC) nel trattamento empirico della neutropenia febbrile Abstract   PDF
Mario Eandi
 
Vol 4, No 4 (2003) Analisi dei costi di buprenorfina vs metadone nella terapia dei soggetti con dipendenza da oppiacei Abstract   PDF
Giorgio L. Colombo, Guido Faillace, Michele Ferdico
 
Vol 3, No 3 (2002) Analisi della persistenza e delle risorse allocate nel trattamento farmacologico dell’ipertensione arteriosa Abstract   PDF
Luca Degli Esposti, Alessandro Capone, Ezio Degli Esposti, Giorgio Valpiani, Mirko Di Martino, Gianluca Baio, Pierluigi Russo, Stefano Buda, Alessandra Sturani, Luciano Caprino
 
Vol 6, No 2 (2005) Analisi di costo di pemetrexed vs docetaxel nel trattamento di seconda linea del carcinoma polmonare non a piccole cellule Abstract   PDF
Roberto Ravasio
 
Vol 6, No 4 (2005) Analisi di costo efficacia nella terapia della BPCO Abstract   PDF
Sergio Iannazzo, Lorenzo Pradelli, Roberto W. Dal Negro, Mario Eandi
 
Vol 5, No 4 (2004) Analisi di minimizzazione dei costi del trattamento della leucemia cronica con fludarabina fosfato (Fludara®) e.v. e p.o.: metodologia e risultati di un’indagine empirica Abstract   PDF
Carlo Lazzaro
 
Vol 6, No 2 (2005) Analisi farmacoeconomica del trattamento di pazienti psicotici cronici con olanzapina, antipsicotici atipici e neurolettici tipici: uno studio regionale Abstract   PDF
Felice Vadruccio, Giovanni Biricolti, Leonardo Mendolicchio
 
Vol 17, No 1 (2016) Analysis of the treatment cost of HIV/AIDS in Turkey Abstract   HTML   PDF
Guvenc Kockaya, Tuba Elbir Zengin, Fatma Betul Yenilmez, Canan Dalgic, Simten Malhan Simten Malhan, Pamir Cerci, Ergun Oksuz, Serhat Unal
 
Vol 11, No 2 (2010) Ankylosing spondylitis and psoriatic arthritis: clinical and economic consequences of the use of etanercept Abstract   PDF
Viola Sacchi, Orietta Zaniolo, Ignazio Olivieri
 
Vol 9, No 1S (2008) Appendice Details   PDF
Maria Caterina Cavallo, Filippo Cipriani, Simone Gerzeli, Nadia Demarteau, Alessia Marocco, Francesco Bamfi
 
Vol 3, No 2 (2002) Appropriatezza clinica ed economica: strumenti e modelli di valutazione e gestione dell’attività psichiatrica Abstract   PDF
Carmine Munizza, Salvatore Nieddu, Maurizio Bianco
 
Vol 13, No 3 (2012) Assessment of the innovative quality of agomelatine through the Innovation Assessment Algorithm Abstract   HTML   PDF
Liliana Civalleri, Sabrina Licata
 
Vol 8, No 2 (2007) Asthma and public awareness in Italy: results from CHAOS (Chronic Airway Obstruction Survey) Abstract   PDF
Stefano Uleri, Roberto W. Dal Negro
 
Vol 8, No 1S (2007) Atti del I Convegno. Laboratorio dose unitaria Galenica clinica e gestione del rischio: modelli ed esperienze Details   PDF
Alessandro D’Arpino, Francesca Venturini, Luigi Giuliani, Ilario Viano, Oscar Alabiso, Massimo Boni, Maria Rachele Chiappetta, Stefano Federici, Franca Goffredo, Antonella Cannas, Paolo Serra
 
Vol 2, No 4 (2001) Automedicazione: una risorsa economica da valorizzare Abstract
Carlo Lucioni, Luca Zappaterra
 
Vol 13, No 2S (2012) Basilicata Abstract   HTML   PDF
Roberto Gasparini, Donatella Panatto, Bruna Dirodi, Rosa Prato, Gianni Amunni, Valter Turello, Luigi Sudano, Paolo Cristoforoni, Sara Boccalini, Paolo Bonanni
 
Vol 9, No 1S (2008) Basilicata Abstract   PDF
Maria Caterina Cavallo, Filippo Cipriani, Simone Gerzeli, Nadia Demarteau, Alessia Marocco, Francesco Bamfi
 
Vol 8, No 1 (2007) Bayesian statistic methods and theri application in probabilistic simulation models Abstract   PDF
Sergio Iannazzo
 
Vol 7, No 1 (2006) Bayesian statistic methods and theri application in probabilistic simulation models Abstract   PDF
Orietta Zaniolo, Mario Eandi
 
Vol 13, No 2S (2012) Bolzano Abstract   HTML   PDF
Roberto Gasparini, Donatella Panatto, Bruna Dirodi, Rosa Prato, Gianni Amunni, Valter Turello, Luigi Sudano, Paolo Cristoforoni, Sara Boccalini, Paolo Bonanni
 
Vol 9, No 1S (2008) Bolzano Abstract   PDF
Maria Caterina Cavallo, Filippo Cipriani, Simone Gerzeli, Nadia Demarteau, Alessia Marocco, Francesco Bamfi
 
Vol 17, No 3 (2016) Budget impact analysis of apixaban to treat and prevent venous thromboembolism in Italy Abstract   HTML   PDF
Marco Bellone, Roberto Di Virgilio, Paolo Di Rienzo
 
Vol 15, No 1S (2014) Budget impact analysis of apixaban versus other NOACs for the prevention of stroke in Italian atrial fibrillation patients Abstract   HTML   PDF
Lorenzo Pradelli, Mario Calandriello, Roberto Di Virgilio, Marco Bellone, Marco Tubaro
 
Vol 18, No 1 (2017) Budget Impact analysis of the first-line treatment of Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) adult patients Abstract   HTML   PDF
Francesco Mennini, Andrea Marcellusi, Raffaella Viti, Giuseppe Saglio
 
Vol 17, No 1 (2016) Budget impact analysis of the use of daclatasvir in Italy for the treatment of Hepatitis C Virus (HCV) genotype 3 patients Abstract   HTML   PDF
Umberto Restelli, Alfredo Alberti, Adriano Lazzarin, Marzia Bonfanti, Carmela Nappi, Davide Croce
 
Vol 10, No 1 (2009) Budget impact analysis of the use of lapatinib in the treatment of breast cancer in Italy Abstract   PDF
Francesco Bamfi, Federica Basso, Massimo Aglietta, Carmelo Bengala, Vito Lorusso, Paolo Pronzato, Maria Caterina Cavallo, Orietta Zaniolo, Sergio Iannazzo
 
Vol 15, No 3 (2014) Budget impact analysis of the use of paricalcitol for the treatment of secondary hyperparathyroidism in chronic kidney disease Abstract   HTML   PDF
Valentina Lorenzoni, Giuseppe Turchetti
 
Vol 10, No 1 (2009) Budget impact analysis of the use of rituximab in the treatment of rheumatoid arthritis in Italy Abstract   PDF
Maurizio Benucci, Sergio Iannazzo, Luciano Sabadini
 
Vol 10, No 1 (2009) Budget impact analysis of use of aliskiren in hypertension on the Italian Health Care System Abstract   PDF
Orietta Zaniolo, Lorenzo Pradelli
 
Vol 13, No 3 (2012) Budget impact analysis resulting from the use of dabigatran etexilate in preventing stroke in patients with non-valvular atrial fibrillation in Italy Abstract   HTML   PDF
Francesco Mennini, Sergio Russo, Andrea Marcellusi
 
Vol 8, No 1 (2007) Budget impact of rosiglitazone in type 2 diabetes Abstract   PDF
Orietta Zaniolo, Francesco Bamfi, Sergio Iannazzo
 
Vol 9, No 3 (2008) Budget impact of vildagliptin Abstract   PDF
Orietta Zaniolo, Viola Sacchi, Lorenzo Pradelli
 
Vol 13, No 2S (2012) Calabria Abstract   HTML   PDF
Roberto Gasparini, Donatella Panatto, Bruna Dirodi, Rosa Prato, Gianni Amunni, Valter Turello, Luigi Sudano, Paolo Cristoforoni, Sara Boccalini, Paolo Bonanni
 
Vol 9, No 1S (2008) Calabria Abstract   PDF
Maria Caterina Cavallo, Filippo Cipriani, Simone Gerzeli, Nadia Demarteau, Alessia Marocco, Francesco Bamfi
 
Vol 13, No 2S (2012) Campania Abstract   HTML   PDF
Roberto Gasparini, Donatella Panatto, Bruna Dirodi, Rosa Prato, Gianni Amunni, Valter Turello, Luigi Sudano, Paolo Cristoforoni, Sara Boccalini, Paolo Bonanni
 
Vol 9, No 1S (2008) Campania Abstract   PDF
Maria Caterina Cavallo, Filippo Cipriani, Simone Gerzeli, Nadia Demarteau, Alessia Marocco, Francesco Bamfi
 
Vol 14, No 1 (2013) Can market structure explain cross-country differences in health? Abstract   HTML   PDF
Kate Rybczynski, Lori Curtis
 
Vol 13, No 1S (2012) Cetuximab in first line treatment of metastatic colorectal cancer Abstract   HTML   PDF
Carlo Barone, Andrea Belisari, Fortunato Ciardiello, Lorenzo Mantovani, Lucia D’Angiolella, Gianluca Furneri, Nicola Normanno, Patrizio Piacentini, Carmine Pinto
 
Vol 13, No 1 (2012) Clinical and economic impact of aliskiren in uncontrolled hypertensive patients Abstract   HTML   PDF
Ezio Degli Esposti, Radovan Tomic
 
Vol 12, No 2 (2011) Clinical and economic profile of entecavir in the treatment of chronic hepatitis b virus infection Abstract   HTML   PDF
Mario Eandi
 
Vol 13, No 3 (2012) Clinical and economic profile of prucalopride in the treatment of chronic constipation in women Abstract   HTML   PDF
Vincenzo Stanghellini, Mario Eandi
 
Vol 7, No 3 (2006) Clinical and pharmacoeconomic profile of esomeprazole in acid-related diseases Abstract   PDF
Orietta Zaniolo
 
Vol 11, No 1 (2010) Clinical and pharmacoeconomic profile of lanthanum carbonate treatment of hyperphosphataemia in chronic renal dialysis patients Abstract   PDF
Mario Eandi
 
Vol 4, No 2 (2003) Commenti al lavoro di Colombo GL, Muzio A “Gli inibitori di pompa protonica nelle patologie acido-correlate: il ruolo di rabeprazolo in una strategia di cost minimisation” Details   PDF
Cristina Rossi, Giancarlo Benelli
 
Vol 6, No 3 (2005) Commenti all’articolo: “Interruzione del trattamento nei pazienti con schizofrenia che ricevono olanzapina o aripiprazolo: metanalisi degli studi clinici controllati” Details   PDF
Giovanni Battista Leproux, Michele Intorcia
 
Vol 15, No 1S (2014) Comparative pharmacoeconomic assessment of apixaban vs. standard of care for the prevention of stroke in Italian atrial fibrillation patients Abstract   HTML   PDF
Lorenzo Pradelli, Mario Calandriello, Roberto Di Virgilio, Marco Bellone, Marco Tubaro
 
Vol 16, No 3 (2015) Comparison between traditional and goal directed perfusion in cardiopulmonary by-pass. A differential cost analysis in US Abstract   HTML   PDF
Massimiliano Povero, Lorenzo Pradelli
 
Vol 16, No 1S (2015) Comparison between traditional and goal directed perfusion in cardiopulmonary by-pass. Adaptation of a differential cost analysis Abstract   HTML   PDF
Massimiliano Povero, Lorenzo Pradelli
 
Vol 4, No 3 (2003) Considerazioni cliniche ed economiche nel trattamento del cancro della prostata: analisi costo-efficacia di bicalutamide vs flutamide in combinazione con LHRH Abstract   PDF
Monia Marchetti, Giorgio Lorenzo Colombo
 
Vol 13, No 2 (2012) Consumer preferences for the predictive genetic tests for Alzheimer’s disease Abstract   HTML   PDF
Ming-Yi Huang, Matthew Perri III
 
Vol 16, No 2 (2015) Cost analysis of inappropriate treatments for suspected dermatomycoses Abstract   HTML   PDF
Emanuela Fiammenghi, Angela Patalano, Viviana Lo Conte, Gabriella Calabrò
 
Vol 16, No 1 (2015) Cost differentials of dental outpatient care across clinical dentistry branches Abstract   HTML   PDF
Jovana Rančić, Nemanja Rančić, Nemanja Majstorović, Vladimir Biočanin, Marko Milosavljević, Mihajlo Jakovljević
 
Vol 17, No 2 (2016) Cost of care of chronic non-communicable diseases in Jamaican patients: the role of obesity Abstract   HTML   PDF
Christine M. Fray-Aiken, Rainford J. Wilks, Abdullahi O. Abdulkadri, Affette M. McCaw-Binns
 
Vol 16, No 3 (2015) Cost of illness of advanced ovarian carcinoma in Italy: results of an empirical, single-centre study Abstract   HTML   PDF
Carlo Lazzaro, Francesco Plotti, Stella Capriglione, Matteo Ferrario, Roberto Angioli
 
Vol 13, No 3 (2012) Cost of illness of community-acquired pneumonia. Review of the literature and possible strategies in the Serbian health care setting Abstract   HTML   PDF
Mihajlo Jakovljevic, Vojislav Cupurdija, Zorica Lazic
 
Vol 12, No 3 (2011) Cost of osteoporosis-related fracture in Italy. Results of the BLOCK study Abstract   HTML   PDF
Luca Degli Esposti, Silvano Adami, Giovanni Iolascon, Alfredo Nardi, Luca Pietrogrande, Giuseppina Resmini, Maurizio Rossini, Umberto Tarantino, Paolo Tranquilli Leali, Carlo Trevisan, Alessandra Cheli, Chiara Veronesi, Stefano Buda
 
Vol 11, No 2 (2010) Cost/effectiveness analysis of atorvastatin in patients with acute coronary syndromes Abstract   PDF
Simona Cammarota, Enrica Menditto, Daria Putignano, Anna Citarella
 
Vol 11, No 2 (2010) Cost/effectiveness model of dabigatran in the prevention of venous thromboembolism in major orthopedic surgery: Adaptation for Italy Abstract   PDF
Orietta Zaniolo, Sorrel E. Wolowacz, Lorenzo Pradelli
 
Vol 7, No 2 (2006) Cost-effectiveness analysis of paclitaxel + carboplatin vs. alternative combinations in the treatment of non-small cell lung cancer Abstract   PDF
Mario Eandi
 
Vol 12, No 2 (2011) Cost-effectiveness evaluations of spinal neuromodulation with ziconotide continuous infusion in cancer pain in a real clinical practice Abstract   HTML   PDF
Orietta Zaniolo, Sergio Iannazzo, Gian Piero Patrucco, Roberto Bellini
 
Vol 15, No 4 (2014) Cost-effectiveness of intravitreal therapy in Age-Related Macular Degeneration Abstract   HTML   PDF
Piergiorgio Neri, Ilir Arapi, Chiara Maria Eandi, Vittorio Pirani, Cesare Mariotti, Alfonso Giovannini
 
Vol 15, No 1 (2014) Cost-effectiveness of tenofovir in the treatment of patients with chronic hepatitis B: data from literature Abstract   HTML   PDF
Massimo Fasano, Giorgio L. Colombo, Sergio Di Matteo, Claudia Randazzo, Gioacchino Angarano, Teresa Antonia Santantonio
 
Vol 17, No 3 (2016) Cost-effectiveness profile, organizational implications and patient preferences on the use of exogenous TSH therapy (Thyrogen®) vs. THW in thyroid residue ablation in Italy Abstract   HTML   PDF
Gianluca De Danieli, Fabio Monari, Renzo Lazzarini, Filippo Cipriani
 
Vol 9, No 3 (2008) Cost-efficacy analysis of hormonal treatments for advanced prostate cancer Abstract   PDF
Sergio Iannazzo, Lorenzo Pradelli
 
Vol 3, No 2 (2002) Costi del trattamento con oloprazina nelle fasi iniziali della schizofrenia Abstract   PDF
Domenico Berardi, Maddalena Dell’Atti, Francesca Russo, Virginia Vagnini, Luca Guidi, Eric T. Edgell
 
Vol 6, No 2 (2005) Costi e bisogni sanitari degli anziani non autosufficienti presso le strutture residenziali: strategie e interventi per una popolazione che invecchia Abstract   PDF
Marta Moro, Chiara Salvato, Gianni Terrazzani, Donatella Serraglia, Cristina Saramin, Pietro Giusti, Alessandro Chinellato
 
Vol 5, No 1 (2004) Costi ed effetti di Risperidone Long Acting (RLA) rispetto ad antipsicotici atipici nel trattamento dei soggetti schizofrenici in Italia Abstract   PDF
Lorenzo G. Mantovani, Patrizia Berto, Anna D. Ausilio, Bart Heeg
 
Vol 4, No 1 (2003) Costi sanitari di un programma vaccinale: analisi di minimizzazione dei costi Abstract   PDF
G. L. Colombo, A. Muzio, R. Giordani
 
Vol 6, No 3 (2005) Costo/efficacia della prevenzione di infezioni alle prime vie aeree mediante un estratto batterico immunostimolante aspecifico (OM-85) Abstract   PDF
Orietta Zaniolo, Lorenzo Pradelli, Mario Eandi
 
Vol 5, No 1 (2004) Costo-efficacia dell’amfotericina B liposomiale nella terapia dell’aspergillosi invasiva Abstract   PDF
Mario Eandi
 
Vol 2, No 1 (2001) Costruzione di un modello decisionale per valutare la costo/efficacia delle strategie alternative nella terapia della polmonite acquisita in comunità Abstract   PDF
Mario Eandi
 
Vol 8, No 2 (2007) Costs and efficacy ofolanzapine and risperidone in schizophrenia Abstract   PDF
Vittorio Mapelli
 
Vol 10, No 2 (2009) Costs of diabetes in Italy Abstract   PDF
Orietta Zaniolo
 
Vol 14, No 2 (2013) Costs of treatment of haemophilia A in Italy: comparison of the use of plasma-derived and recombinant FVIII using a discrete event simulation (DES) model Abstract   HTML   PDF
Mario Eandi, Lorenzo Pradelli, Massimiliano Povero
 
Vol 9, No 1 (2008) Cost-utility analysis of abatacept in rheumatoid arthritis in Italy Abstract   PDF
Simona de Portu, Lorenzo Giovanni Mantovani, Ignazio Olivieri
 
Vol 15, No 4 (2014) Cost‑effectiveness analysis of apixaban versus other NOACs for the prevention of stroke in Italian atrial fibrillation patients Abstract   HTML   PDF
Lorenzo Pradelli, Mario Calandriello, Roberto Di Virgilio, Marco Bellone, Marco Tubaro
 
Vol 15, No 3 (2014) Cost‑effectiveness analysis of hexaminolevulinate (Hexvix®) guided cystoscopy in Non‑Muscle Invasive Bladder Cancer patients (NMIBC) in Italy Abstract   HTML   PDF
Craig Bennison, Stephanie Stephens, Giario Natale Conti
 
Vol 13, No 1 (2012) Could the choice of patient versus proxy ratings for assessing quality of life in dementia affect resource allocation in health care? Abstract   HTML   PDF
Jenny Alwin, Thor-Henrik Brodtkorb
 
Vol 1, No 1 (2000) Creare Valore Sanitario: nuove prospettive per il management delle aziende sanitarie Abstract   PDF
Giorgio Donna, Salvatore Nieddu
 
Vol 1, No 2 (2000) Creazione di valore sanitario e sistemi di finanziamento: il caso del dipartimento di salute mentale Abstract   PDF
Carmine Munizza, Salvatore Nieddu
 
Vol 10, No 3 (2009) Dabigatran in the prevention of venous thromboembolism after major orthopedic surgery Abstract   PDF
Orietta Zaniolo
 
Vol 9, No 3 (2008) Daptomycin (Cubicin) in patients with complicated skin or soft-tissue infections Abstract   PDF
Viola Sacchi
 
1 - 100 of 416 Items 1 2 3 4 5 > >>